The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure
Abstract
Heart failure is a progressive muscular disorder leading to a deterioration of the heart characterized by a contractile dysfunction and a chronic energy deficit. As a consequence, the failing heart is unable to meet the normal metabolic and energy needs of the body. The transition between compensated left ventricular hypertrophy and the de-compensated heart is multifactorial, although metabolic disturbances are considered to play a significant role. In this respect, the AMP-activated protein kinase (AMPK) could be a potential target in heart failure development. AMPK senses the energy state of the cell and orchestrates a global metabolic response to energy deprivation. We briefly review here the current knowledge about the chronic energy deficit of the failing heart, as well as the role of AMPK in energy homeostasis and in the control of non-metabolic targets in relation to cardiac hypertrophy and heart failure. The relative importance of energetic and non-metabolic effects in the potential cardioprotective action of AMPK is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 4×
“We speculate that they could instead result from non-metabolic effects, which include anti-proliferative, anti-fibrotic, and angiogenic effects of AMPK.”
BackgroundInfluentialAMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., et al. (2003) · Nature · doi:10.1038/nature01960 · Cited by 3,796 · cited 2×
“It was initially thought that the anti-ageing effects of resveratrol were mediated by SIRT1.(73) However, resveratrol also activates AMPK, probably by inhibiting mitochondrial respiration,(74)”
BackgroundKahn, B. B., Alquier, T., Carling, D., & Hardie, D. G. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2004.12.003 · Cited by 2,799
AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α
Jäger, S., Handschin, C., St.-Pierre, J., & Spiegelman, B. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705070104 · Cited by 2,491
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157 · cited 1×
“Their initial metabolic effect is to inhibit mitochondrial respiration, thus decreasing ATP production.(66,67) It should however be noted that several effects of metformin are thought”
BackgroundULK-Atg13-FIP200 Complexes Mediate mTOR Signaling to the Autophagy Machinery
Jung, C. H., Jun, C. B., Ro, S.-H., Kim, Y.-M., Otto, N. M., Cao, J., Kundu, M., & Kim, D.-H. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-12-1249 · Cited by 2,025
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911 · cited 2×
“It is mediated by the phosphorylation of upstream controlling elements, such as tuberous sclerosis complex 2 (TSC2) and/or Raptor.84,85 Downstream of mTOR, p70 ribosomal S6 protein kinase (p70S6K), and 4E-binding protein-1 (4EBP1) are involved in protein translation and cell growth.83,86 In addition, AMPK directly pho…”
BackgroundHawley, S. A., Pan, D. A., Mustard, K. J., Ross, L., Bain, J., Edelman, A. M., Frenguelli, B. G., & Hardie, D. G. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.009 · Cited by 1,589
Cited by
Cardiac Metabolism in Heart Failure: Implications Beyond ATP Production
Doenst, T., Nguyen, T. D., & Abel, E. D. (2013) · Circulation Research · doi:10.1161/circresaha.113.300376 · Cited by 1,111
Antioxidant effects of resveratrol in the cardiovascular system
Xia, N., Daiber, A., Förstermann, U., & Li, H. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13492 · Cited by 574
Srivastava, R. A. K., Pinkosky, S. L., Filippov, S., Hanselman, J. C., Cramer, C. T., & Newton, R. S. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r025882 · Cited by 296
Cardiovascular effects and molecular targets of resveratrol
Li, H., Xia, N., & Förstermann, U. (2012) · Nitric Oxide · doi:10.1016/j.niox.2011.12.006 · Cited by 287
AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation
Gélinas, R., Mailleux, F., Dontaine, J., Bultot, L., Demeulder, B., Ginion, A., Daskalopoulos, E. P., Esfahani, H., Dubois-Deruy, E., Lauzier, B., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02795-4 · Cited by 253
Self-citationTherapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models
Ogura, Y., Ouchi, N., Ohashi, K., Shibata, R., Kataoka, Y., Kambara, T., Kito, T., Maruyama, S., Yuasa, D., Matsuo, K., et al. (2012) · Circulation · doi:10.1161/circulationaha.112.115089 · Cited by 183
The role of oxytocin in cardiovascular regulation
Gutkowska, J., Jankowski, M., & Antunes-Rodrigues, J. (2014) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20133309 · Cited by 131
“The activation of AMPK in the heart following ischemia and reperfusion is recognized as cardioprotective, because AMPK limits apoptosis and suppresses cardiac pathological hypertrophy (52).”
BackgroundZhou, X., Ma, L., Habibi, J., Whaley-Connell, A., Hayden, M. R., Tilmon, R. D., Brown, A. N., Kim, J.-A., DeMarco, V. G., & Sowers, J. R. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.145136 · Cited by 116
AMPK negatively regulates tensin-dependent integrin activity
Georgiadou, M., Lilja, J., Jacquemet, G., Guzmán, C., Rafaeva, M., Alibert, C., Yan, Y., Sahgal, P., Lerche, M., Manneville, J.-B., et al. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201609066 · Cited by 109
“Recently, AMPK activation has been shown to ameliorate fibrosis in several tissues, and AMPK activators have been suggested as potential therapeutics in the treatment of the aforementioned diseases (Beauloye et al., 2011; Satriano et al., 2013).”
Inhibition of Angiotensin II‐Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice
Choi, S. Y., Park, J. S., Roh, M. S., Kim, C., Kim, M. H., & Serebruany, V. (2017) · Lipids · doi:10.1007/s11745-017-4246-1 · Cited by 15
Metadata
- Authors
- Beauloye, C., Bertrand, L., Horman, S., & Hue, L.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-02-01
- Volume
- 90
- Issue
- 2
- Pages
- 224-233
- ISSN
- 0008-6363 (ISSN-L)
- OpenAlex
- W2023907177
- Cited by
- 187
- References
- 40
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.